Изучение биологических активностей мутантных форм белка р53

Список литературы

1. Abarzua, P., J. E. LoSardo, M. L. Gubler, and A. Neri. 1995. Microinjection of monoclonal antibody PAb421 into human SW480 colorectal carcinoma cells restores the transcription activation function to mutant p53. Cancer Res 55:3490−4.
2. Abarzua, P., J. E. LoSardo, M. L. Gubler, R. Spathis, Y. A. Lu, A. Felix, and A. Neri.1996. Restoration of the transcription activation function to mutant p53 in human cancer cells. Oncogene 13:2477−82.
3. Abrahamson, J. L., J. M. Lee, and A. Bernstein. 1995. Regulation of p53-mediated apoptosis and cell cycle arrest by Steel factor. Mol Cell Biol 15:6953−60.
4. Kopnin. 1996. Chromosome changes caused by alterations of p53 expression. Mutat Res 354:12 938.
5. Agarwal, M. L., A. Agarwal, W. R Taylor, Z. Q. Wang, E. F. Wagner, and G. R. Stark.1997. Defective induction but normal activation and function of p53 in mouse cells lacking poly-ADP-ribose polymerase. Oncogene 15:1035−41.
6. Agoff, S. N., J. Hou, D. I. Linzer, and B. Wu. 1993. Regulation of the human hsp70 promoter by p53. Science 259:84−7.
7. An, W. G., M. Kanekal, M. C. Simon, E. Maltepe, M. V. Blagosklonny, and L. M. Neckers.1998. Stabilization of wild-type p53 by hypoxia-inducible factor 1 alpha. Nature 392:405−8.
8. Avantaggiati, M. L., V. Ogryzko, K. Gardner, A. Giordano, A. S. Levine, and K. Kelly. 1997. Recruitment ofp300/CBP in p53-dependent signal pathways. Cell 89:1175−84.
9. Banin, S., L. Moyal, S. Shieh, Y. Taya, C. W. Anderson, L. Chessa, N. I. Smorodinsky, C. Prives, Y. Reiss, Y. Shiloh, and Y. Ziv. 1998. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281:1674−7.
10. Barak, Y., E. Gottlieb, T. Juven-Gershon, and M. Oren. 1994 Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev 8:1739−49.
11. Barlow, C., K. D. Brown, C. X. Deng, D. A. Tagle, and A. Wynshaw-Boris. 1997 Atm selectively regulates distinct p53-dependent cell-cycle checkpoint and apoptotic pathways published erratum appears in Nat Genet 1998 Mar-18(3):298., Nat Genet 17:453−6.
12. Baudier, J., C. Delphin, D. Grunwald, S. Khochbin, and J. J. Lawrence. 1992. Characterization of the tumor suppressor protein p53 as a protein kinase C substrate and a SI00b-binding protein. Proc Natl Acad Sci U S A 89:11 627−31.
13. Bennett, M., K. Macdonald, S. W. Chan, J. P. Luzio, R. Simari, and P. Weissberg.1998. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science 282:290−3.
14. Bian, J., and Y. Sun. 1997. Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. Mol Cell Biol 17:6330−8.
15. Bischoff, J. R., P. N. Friedman, D. R. Marshak, C. Prives, and D. Beach. 1990 Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. Proc Natl Acad Sci U S A 87:4766−70.
16. Blagosklonny, M. V., W. G. An, L. Y. Romanova, J. Trepel, T. Fojo, and L. Neckers. 1998. p53 inhibits hypoxia-inducible factor-stimulated transcription. J Biol Chem 273:11 995−8.
17. Blagosklonny, M. V., J. Toretsky, S. Bohen, and L. Neckers. 1996. Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. Proc Natl Acad Sci U S A 93:837 983.
18. Blagosklonny, M. V., J. Toretsky, and L. Neckers. 1995. Geldanamycin selectively destabilizes and conformationally alters mutated p53. Oncogene 11:933−9.
19. Blondal, J. A., and S. Benchimol. 1994. The role of p53 in tumor progression. Semin Cancer Biol 5:177−86.
20. Boddy, M. N., P. S. Freemont, and K. L. Borden. 1994. The p53-associated protein MDM2 contains a newly characterized zinc- binding domain called the RING finger. Trends Biochem Sci 19:198−9.
21. Brain, R., and J. R. Jenkins. 1994. Human p53 directs DNA strand reassociation and is photolabelled by 8- azido ATP. Oncogene 9:1775−80.
22. Buckbinder, L., R. Talbott, S. Velasco-Miguel, I. Takenaka, B. Faha, B. R. Seizinger, and N. Kley. 1995. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377:646−9.
23. Buckbinder, L., S. Velasco-Miguel, Y. Chen, N. Xu, R Talbott, L. Gelbert, J. Gao, B. R. Seizinger, J. S. Gutkind, and N. Kley. 1997. The p53 tumor suppressor targets a novel regulator of G protein signaling. Proc Natl Acad Sci U S A 94:7868−72.
24. Caelles, C., A. Helmberg, and M. Karin. 1994. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes see comments. Nature 370:220−3.
25. Castedo, M., A. Macho, N. Zamzami, T. Hirsch, P. Marchetti, J. Uriel, and G. Kroemer. 1995. Mitochondrial perturbations define lymphocytes undergoing apoptotic depletion in vivo. Eur J Immunol 25:3277−84.
26. Cavenee, W. K., H. J. Scrable, and C. D. James. 1991. Molecular genetics of human cancer predisposition and progression. Mutat Res 247:199−202.
27. Chen, J., X. Wu, J. Lin, and A. J. Levine. 1996. mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol 16:2445−52.
28. Chen, X., L. J. Ko, L. Jayaraman, and C. Prives. 1996. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev 10:2438−51.
29. Chen, Y., P. L. Chen, and W. H. Lee. 1994. Hot-spot p53 mutants interact specifically with two cellular proteins during progression of the cell cycle. Mol Cell Biol 14:6764−72.
30. Cheng, J., and M. Haas. 1990. Frequent mutations in the p53 tumor suppressor gene in human leukemia T- cell lines. Mol Cell Biol 10:5502−9.
31. Chin, K. V., K. Ueda, L Pastan, and M. M. Gottesman. 1992. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255:459−62.
32. Chitpatima, S. T., S. Makrides, R. Bandyopadhyay, and G. Brawerman. 1988 Nucleotide sequence of a major messenger RNA for a 21 kilodalton polypeptide that is under translational control in mouse tumor cells. Nucleic Acids Res 16:2350.
33. Cho, Y., S. Gorina, P. D. Jeffrey, and N. P. Pavletich. 1994. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations see comments. Science 265:346−55.
34. Chumakov, A. M., C. W. Miller, D. L. Chen, and H. P. Koeffler. 1993 Analysis of p53 transactivation through high-affinity binding sites. Oncogene 8:3005−11.
35. Coles, C., A. Condie, U. Chetty, C. M. Steel, H. J. Evans, and J. Prosser. 1992 p53 mutations in breast cancer. Cancer Res 52:5291−8.
36. Cook, A., and J. Milner. 1990. Evidence for allosteric variants of wild-type p53, a tumour suppressor protein. Br J Cancer 61:548−52.
37. Cordon-Cardo, C., E. Latres, M. Drobnjak, M. R. Oliva, D. Pollack, J. M. Woodruff, V. Marechal, J. Chen, M. F. Brennan, and A. J. Levine. 1994. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 54:794−9.
38. Crook, T., N. J. Marston, E. A. Sara, and K. H. Vousden. 1994. Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell 79:817−27.
39. Cross, S. M., C. A. Sanchez, C. A. Morgan, M. K. Schimke, S. Ramel, R. L. Idzerda, W. H. Raskind, and B. J. Reid. 1995. A p53-dependent mouse spindle checkpoint. Science 267:1353−6.
40. Deb, S., C. T. Jackson, M. A. Subler, and D. W. Martin. 1992. Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells. J Virol 66:6164−70.
41. Deb, S. P., R. M. Munoz, D. R. Brown, M. A. Subler, and S. Deb. 1994 Wild-type human p53 activates the human epidermal growth factor receptor promoter. Oncogene 9:1341−9.
42. Demers, G. W., S. A. Foster, C. L. Halbert, and D. A. Galloway. 1994 Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7. Proc Natl Acad Sci U S A 91:4382−6.
43. Donato, N. J., and M. Perez. 1998. Tumor necrosis factor-induced apoptosis stimulates p53 accumulation and p21WAFl proteolysis in ME-180 cells. J Biol Chem 273:5067−72.
44. Donehower, L. A., M. Harvey, B. L. Slagle, M. J. McArthur, C. A. Montgomery, Jr., J. S. Butel, and A. Bradley. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215−21.
45. Elenbaas, B., M. Dobbelstein, J. Roth, T. Shenk, and A. J. Levine. 1996 The MDM2 oncoprotein binds specifically to RNA through its RING finger domain. Mol Med 2:439−51.
46. Eliyahu, D., D. Michalovitz, S. Eliyahu, O. Pinhasi-Kimhi, and M. Oren. 1989 Wildtype p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci U S A 86:8763−7.
47. Eliyahu, D., A. Raz, P. Gruss, D. Givol, and M. Oren. 1984. Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature 312:646−9.
48. Fakharzadeh, S. S., S. P. Trusko, and D. L. George. 1991. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. Embo J 10:1565−9.
49. Farmer, G., J. Bargonetti, H. Zhu, P. Friedman, R. Prywes, and C. Prives. 1992 Wildtype p53 activates transcription in vitro see comments. Nature 358:83−6.
50. Fields, S., and S. K. Jang. 1990. Presence of a potent transcription activating sequence in the p53 protein. Science 249:1046−9.
51. Finlay, C. A. 1993. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol 13:301−6.
52. Finlay, C. A., P. W. Hinds, T. H. Tan, D. Eliyahu, M. Oren, and A. J. Levine. 1988 Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 8:531−9.
53. Forrester, K., S. E. Lupoid, V. L. Ott, C. H. Chay, V. Band, X. W. Wang, and C. C. Harris. 1995. Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. Oncogene 10:2103−11.
54. Frebourg, T., M. Sadelain, Y. S. Ng, J. Kassel, and S. H. Friend. 1994 Equal transcription of wild-type and mutant p53 using bicistronic vectors results in the wild-type phenotype. Cancer Res 54:878−81.
55. Freedman, D. A., and A. J. Levine. 1998. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6 In Process Citation., Mol Cell Biol 18:7288−93.
56. Fuchs, S. Y., V. Adler, T. Buschmann, Z. Yin, X. Wu, S. N. Jones, and Z. Ronai. 1998 JNK targets p53 ubiquitination and degradation in nonstressed cells. Genes Dev 12:2658−63.
57. Fuchs, S. Y., V. Adler, M. R Pincus, and Z. Ronai. 1998. MEKK1/JNK signaling stabilizes and activates p53. Proc Natl Acad Sci U S A 95:10 541−6.
58. Fukasawa, K., T. Choi, R. Kuriyama, S. Rulong, and G. F. Vande Woude. 1996 Abnormal centrosome amplification in the absence of p53. Science 271:1744−7.
59. Funk, W. D., D. T. Pak, R. H. Karas, W. E. Wright, and J. W. Shay. 1992 A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol 12:2866−71.
60. Giaccia, A. J., and M. B. Kastan. 1998. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev 12:2973−83.
61. Gibson, C. W., S. R. Rittling, R. R. Hirschhorn, L. Kaczmarek, B. Calabretta, C. D. Stiles, and R. Baserga. 1986. Cell cycle dependent genes inducible by different mitogens in cells from different species. Mol Cell Biochem 71:61−9.
62. Ginsberg, D., F. Mechta, M. Yaniv, and M. Oren. 1991. Wild-type p53 can down-modulate the activity of various promoters. Proc Natl Acad Sci U S A 88:9979−83.
63. Gloushankova, N., V. Ossovskaya, J. Vasiliev, P. Chumakov, and B. Kopnin. 1997. Changes in p53 expression can modify cell shape of ras-transformed fibroblasts and epitheliocytes. Oncogene 15:2985−9.
64. Gossen, M., and H. Bujard. 1992. Tight control of gene expression in mammalian cells by tetracycline- responsive promoters. Proc Natl Acad Sci U S A 89:5547−51.
65. Gottlieb, E., and M. Oren. 1998. p53 facilitates pRb cleavage in EL-3-deprived cells: novel pro- apoptotic activity of p53. Embo J 17:3587−96.
66. Graeber, T. G., C. Osmanian, T. Jacks, D. E. Housman, C. J. Koch, S. W. Lowe, and A. J. Giaccia. 1996. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours see comments. Nature 379:88−91.
67. Gu, W., and R. G. Roeder. 1997. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90:595−606.
68. Gu, W., X. L. Shi, and R. G. Roeder. 1997. Synergistic activation of transcription by CBP and p53. Nature 387:819−23.
69. Gualberto, A., and A. S. Baldwin, Jr. 1995. p53 and Spl interact and cooperate in the tumor necrosis factor-induced transcriptional activation of the HIV-1 long terminal repeat. J Biol Chem 270:19 680−3.
70. Gualberto, A., M. L. Hixon, T. S. Finco, N. D. Perkins, G. J. Nabel, and A. S. Baldwin,
71. Jr. 1995. A proliferative p53-responsive element mediates tumor necrosis factor alpha induction of the human immunodeficiency virus type 1 long terminal repeat. Mol Cell Biol 15:3450−9.
72. Haber, D. A., and D. E. Housman. 1991. Rate-limiting steps: the genetics of pediatric cancers. Cell 64:5−8.
73. Hainaut, P., N. Rolley, M. Davies, and J. Milner. 1995. Modulation by copper of p53 conformation and sequence-specific DNA binding: role for Cu (II)/Cu (I) redox mechanism. Oncogene 10:27−32.
74. Hainaut, P., T. Soussi, B. Shomer, M. Hollstein, M. Greenblatt, E. Hovig, C. C. Harris, and R. Montesano. 1997. Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res 25:151−7.
75. Hall, S. R., L. E. Campbell, and D. W. Meek. 1996. Phosphorylation of p53 at the casein kinase II site selectively regulates p53-dependent transcriptional repression but not transactivation. Nucleic Acids Res 24:1119−26.
76. Han, J., P. Sabbatini, D. Perez, L. Rao, D. Modha, and E. White. 1996. The E1B 19Kprotein blocks apoptosis by interacting with and inhibiting the p53-inducible and death-promoting Bax protein. Genes Dev 10:461−77.
77. Haupt, Y., R. Maya, A. Kazaz, and M. Oren. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387:296−9.
78. Haupt, Y., and M. Oren. 1996. p53-mediated apoptosis: mechanisms and regulation. Behring Inst Mitt :32−59.
79. Haupt, Y., S. Rowan, and M. Oren. 1995. p53-mediated apoptosis in HeLa cells can be overcome by excess pRB. Oncogene 10:1563−71.
80. Haupt, Y., S. Rowan, E. Shaulian, A. Kazaz, K. Vousden, and M. Oren. 1997 p53 mediated apoptosis in HeLa cells: transcription dependent and independent mechanisms. Leukemia 11 Suppl 3:337−9
81. Hermeking, H., C. Lengauer, K. Polyak, T. C. He, L. Zhang, S. Thiagalingam, K. W. Kinzler, and B. Vogelstein. 1997. 14−3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1:3−11.
82. Hickman, E. S., S. M. Picksley, and K. H. Vousden. 1994. Cells expressing HPV16 E7 continue cell cycle progression following DNA damage induced p53 activation. Oncogene 9:217 781.
83. Hinds, P. W., C. A. Finlay, A. B. Frey, and A. J. Levine. 1987. Immunological evidence for the association of p53 with a heat shock protein, hsc70, in p53-plus-ras-transformed cell lines. Mol Cell Biol 7:2863−9.
84. Hollstein, M., T. Soussi, G. Thomas, M. C. von Brevern, and Bartsch, 2nd. 1997 P53 gene alterations in human tumors: perspectives for cancer control. Recent Results Cancer Res 143:369−89.
85. Honda, R., H. Tanaka, and H. Yasuda. 1997. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420:25−7.
86. Hsu, I. C., R. A. Metcalf, T. Sun, J. A. Welsh, N. J. Wang, and C. C. Harris. 1991 Mutational hotspot in the p53 gene in human hepatocellular carcinomas see comments. Nature 350:427−8.
87. Hu, M. C., W. R. Qiu, and Y. P. Wang. 1997. JNK1, JNK2 and JNK3 are p53 N-terminal serine 34 kinases. Oncogene 15:2277−87.
88. Hubank, M., and D. G. Schatz. 1994. Identifying differences in mRNA expression by representational difference analysis of cDNA. Nucleic Acids Res 22:5640−8.
89. Hudson, J. M., R. Frade, and M. Bar-Eli. 1995. Wild-type p53 regulates its own transcription in a cell-type specific manner. DNA Cell Biol 14:759−66.
90. Hupp, T. R., and D. P. Lane. 1994. Allosteric activation of latent p53 tetramers. Curr Biol 4:865−75.
91. Iggo, R., K. Gatter, J. Bartek, D. Lane, and A. L. Harris. 1990. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335:675−9.
92. Ильинская, Г. В., E. H. Пугачева, О. И. Сокова, П. М. Чумаков, Б. П. Копнин.1995. Р53 с мутацией в кодоне 273 увеличивает вероятность амплификации гена dhfr в клетках Rat-1 и Е1М1215.Генетика. 31:611−6.
93. Israeli, D., Е. Tessler, Y. Haupt, A. Elkeles, S. Wilder, R. Amson, A. Telerman, and M.
94. Oren. 1997. A novel p53-inducible gene, PAG608, encodes a nuclear zinc finger protein whose overexpression promotes apoptosis. Embo J 16:4384−92.
95. Jamal, S., and E. B. Ziff. 1995. Raf phosphorylates p53 in vitro and potentiates p53-dependent transcriptional transactivation in vivo. Oncogene 10:2095−101.
96. Jayaraman, L., E. Freulich, and C. Prives. 1997. Functional dissection of p53 tumor suppressor protein. Methods Enzymol 283:245−56.
97. Jayaraman, L., N. C. Moorthy, K. G. Murthy, J. L. Manley, M. Bustin, and C. Prives.1998. High mobility group protein-1 (HMG-1) is a unique activator of p53. Genes Dev 12:462−72.
98. Jenkins, J. R., P. Chumakov, C. Addison, H. W. Sturzbecher, and A. Wade-Evans.1988. Two distinct regions of the murine p53 primary amino acid sequence are implicated in stable complex formation with simian virus 40 T antigen. J Virol 62:3903−6.
99. Jenkins, J. R., K. Rudge, and G. A. Currie. 1984. Cellular immortalization by a cDNA clone encoding the transformation- associated phosphoprotein p53. Nature 312:651−4.
100. Johnson, T. M., Z. X. Yu, V. J. Ferrans, R. A. Lowenstein, and T. Finkel. 1996 Reactive oxygen species are downstream mediators of p53-dependent apoptosis. Proc Natl Acad SciUS A93:11 848−52.
101. Jones, S. N., A. E. Roe, L. A. Donehower, and A. Bradley. 1995. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378:206−8.
102. Jost, C. A., M. C. Marin, and W. G. Kaelin, Jr. 1997. p73 is a human p53-related protein that can induce apoptosis see comments. Nature 389:191−4.
103. Kamijo, T., J. D. Weber, G. Zambetti, F. Zindy, M. F. Roussel, and C. J. Sherr. 1998 Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci U S A 95:8292−7.
104. Kamijo, T., F. Zindy, M. F. Roussel, D. E. Quelle, J. R. Downing, R. A. Ashmun, G. Grosveld, and C. J. Sherr. 1997. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product pl9ARF. Cell 91:649−59.
105. Kastan, M. В., A. I. Radin, S. J. Kuerbitz, О. Onyekwere, С. A. Wolkow, С. I. Civin, K. D. Stone, T. Woo, Y. Ravindranath, and R. W. Craig. 1991. Levels of p53 protein increase with maturation in human hematopoietic cells. Cancer Res 51:4279−86.
106. Kern, S. E., K. W. Kinzler, A. Bruskin, D. Jarosz, P. Friedman, C. Prives, and B. Vogelstein. 1991. Identification of p53 as a sequence-specific DNA-binding protein. Science 252:1708−11.
107. Ко, L. J., and C. Prives. 1996. p53: puzzle and paradigm. Genes Dev 10:1054−72.
108. Ко, L. J., S. Y. Shieh, X. Chen, L. Jayaraman, K. Tamai, Y. Taya, C. Prives, and Z. Q. Pan. 1997. p53 is phosphorylated by CDK7-cyclin H in a p36MATl-dependent manner. Mol Cell Biol 17:7220−9.
109. Кондратов, P. В., H. В. Кузнецов, E. H. Пугачева, В. П. Алмазов, В. С. Прасолов, Б. П. Копнин, П. М. Чумаков. 1996. Функциональная гетерогенность р53-респонсивных элементов. Молекулярная биология 30:613−20.
110. Кондратов Р. В., Е. Н. Пугачева, Н. В. Кузнецов, В. П. Прасолов, Б. П. Копнин, П. М. Чумаков. 1996. Ген аденозин дезоминазы человека содержит р53-респонсивный элемент. ДАН 346:260−262.
111. Koumenis, C., and A. Giaccia. 1997. Transformed cells require continuous activity of RNA polymerase II to resist oncogene-induced apoptosis. Mol Cell Biol 17:7306−16.
112. Kubbutat, M. H., S. N. Jones, and K. H. Vousden. 1997. Regulation of p53 stability by Mdm2. Nature 387:299−303.
113. Kubbutat, M. H., R. L. Ludwig, M. Ashcroft, and K. H. Vousden. 1998. Regulation of Mdm2-directed degradation by the C terminus of p53. Mol Cell Biol 18:5690−8.
114. Kubbutat, M. H., and K. H. Vousden. 1997. Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability. Mol Cell Biol 17:460−8.
115. Kuerbitz, S. J., B. S. Plunkett, W. V. Walsh, and M. B. Kastan. 1992 Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci U S A 89:7491−5.
116. Kulesz-Martin, M. F., B. Lisafeld, H. Huang, N. D. Kisiel, and L. Lee. 1994 Endogenous p53 protein generated from wild-type alternatively spliced p53 RNA in mouse epidermal cells. Mol Cell Biol 14:1698−708.
117. Lamb, P., and L. Crawford. 1986. Characterization of the human p53 gene. Mol Cell Biol 6:1379−85.
118. Lane, D., and E. Harlow. 1982. Two different viral transforming proteins bind the same host tumour antigen news. Nature 298:517.
119. Lane, D. P. 1992. Cancer. p53, guardian of the genome news- comment. [see comments]. Nature 358:15−6.
120. Lechner, M. S., and L. A. Laimins. 1994. Inhibition of p53 DNA binding by human papillomavirus E6 proteins. J Virol 68:4262−73.
121. Lee, F., R. Mulligan, P. Berg, and G. Ringold. 1981. Glucocorticoids regulate expression of dihydrofolate reductase cDNA in mouse mammary tumour virus chimaeric plasmids. Nature 294:228−32.
122. Lee, J. M. 1998. Inhibition of p53-dependent apoptosis by the KIT tyrosine kinase: regulation of mitochondrial permeability transition and reactive oxygen species generation. Oncogene 17:1653−62.
123. Lee, J. M., J. L. Abrahamson, R. Kandel, L. A. Donehower, and A. Bernstein. 1994. Susceptibility to radiation-carcinogenesis and accumulation of chromosomal breakage in p53 deficient mice. Oncogene 9:3731−6.
124. Lees-Miller, S. P., Y. R. Chen, and C. W. Anderson. 1990. Human cells contain a DNA-activated protein kinase that phosphorylates simian virus 40 T antigen, mouse p53, and the human Ku autoantigen. Mol Cell Biol 10:6472−81.
125. Lees-Miller, S. P., K. Sakaguchi, S. J. Ullrich, E. Appella, and C. W. Anderson. 1992 Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53. Mol Cell Biol 12:5041−9.
126. Lehar, S. M., M. Nacht, T. Jacks, C. A. Vater, T. Chittenden, and B. C. Guild. 1996 Identification and cloning of EI24, a gene induced by p53 in etoposide- treated cells. Oncogene 12:1181−7.
127. Li, B., J. M. Rosen, J. McMenamin-Balano, W. J. Muller, and A. S. Perkins. 1997 neu/ERBB2 cooperates with p53−172H during mammary tumorigenesis in transgenic mice. Mol Cell Biol 17:3155−63.
128. Lill, N. L., S. R. Grossman, D. Ginsberg, J. DeCaprio, and D. M. Livingston. 1997 Binding and modulation of p53 by p300/CBP coactivators. Nature 387:823−7.
129. Lin, J., J. Chen, B. Elenbaas, and A. J. Levine. 1994. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev 8:1235−46.
130. Lin, J., A. K. Teresky, and A. J. Levine. 1995. Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants. Oncogene 10:2387−90.
131. Livingstone, L. R., A. White, J. Sprouse, E. Livanos, T. Jacks, and T. D. Tlsty. 1992 Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923−35.
132. Ljungman, M., and F. Zhang. 1996. Blockage of RNA polymerase as a possible trigger for u.v. light-induced apoptosis. Oncogene 13:823−31.
133. Lopes, U. G., P. Erhardt, R. Yao, and G. M. Cooper. 1997. p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem 272:12 893−6.
134. Lotem, J., and L. Sachs. 1995. Interferon-gamma inhibits apoptosis induced by wild-type p53, cytotoxic anti-cancer agents and viability factor deprivation in myeloid cells. Leukemia 9:685−92.
135. Lowe, S. W., S. Bodis, N. Bardeesy, A. McClatchey, L. Remington, H. E. Ruley, D. E. Fisher, T. Jacks, J. Pelletier, and D. E. Housman. 1994. Apoptosis and the prognostic significance ofp53 mutation. Cold Spring Harb Symp Quant Biol 59:419−26.
136. Lowe, S. W., T. Jacks, D. E. Housman, and H. E. Ruley. 1994. Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. Proc Natl Acad Sci U S A 91:2026−30.
137. Lu, H., and A. J. Levine. 1995. Human TAFII31 protein is a transcriptional coactivator of the p53 protein. Proc Natl Acad Sci U S A 92:5154−8.
138. Lu, H., J. Lin, J. Chen, and A. J. Levine. 1994. The regulation of p53-mediated transcription and the roles of hTAFII31 and mdm-2. Harvey Lect 90:81−93.
139. Mack, D. H., J. Vartikar, J. M. Pipas, and L. A. Laimins. 1993. Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53. Nature 363:281−3.
140. Mansur, C. P., B. Marcus, S. Dalai, and E. J. Androphy. 1995 The domain of p53 required for binding HPV 16 E6 is separable from the degradation domain. Oncogene 10:457−65.
141. Marchetti, P., M. Castedo, S. A. Susin, N. Zamzami, T. Hirsch, A. Macho, A. Haeffner, F. Hirsch, M. Geuskens, and G. Kroemer. 1996. Mitochondrial permeability transition is a central coordinating event of apoptosis. J Exp Med 184:1155−60.
142. Marsters, S. A., J. P. Sheridan, R. M. Pitti, J. Brush, A. Goddard, and A. Ashkenazi. 1998. Identification of a ligand for the death-domain-containing receptor Apo3. Curr Biol 8:525−8.
143. Martin, K., D. Trouche, C. Hagemeier, and T. Kouzarides. 1995. Regulation of transcription by E2F1/DP1. J Cell Sci Suppl 19:91−4.
144. Matsuzawa, S., S. Takayama, B. A. Froesch, J. M. Zapata, and J. C. Reed. 1998 p53-inducible human homologue of Drosophila seven in absentia (Siah) inhibits cell growth: suppression by BAG-1. Embo J 17:2736−47.
145. Meek, D. W. 1997. Post-translational modification of p53 and the integration of stress signals. Pathol Biol (Paris) 45:804−14.
146. Midgley, C. A., and D. P. Lane. 1997. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 15:1179−89.
147. Miller, C. W., A. Chumakov, J. Said, D. L. Chen, A. Aslo, and H. P. Koeffler. 1993 Mutant p53 proteins have diverse intracellular abilities to oligomerize and activate transcription. Oncogene 8:1815−24.
148. Milne, D. M., D. G. Campbell, F. B. Caudwell, and D. W. Meek. 1994. Phosphorylation of the tumor suppressor protein p53 by mitogen- activated protein kinases. J Biol Chem 269:925 360.
149. Milne, D. M., R. H. Palmer, D. G. Campbell, and D. W. Meek. 1992 Phosphorylation of the p53 tumour-suppressor protein at three N- terminal sites by a novel casein kinase I-like enzyme. Oncogene 7:1361−9.
150. Milner, J. 1995. Flexibility: the key to p53 function? Trends Biochem Sci 20:49−51.
151. Milner, J., and E. A. Medcalf. 1991. Cotranslation of activated mutant p53 with wild type drives the wild- type p53 protein into the mutant conformation. Cell 65:765−74.
152. Milner, J., and E. A. Medcalf. 1990. Temperature-dependent switching between «wildtype» and «mutant» forms of p53-Vall35. JMol Biol 216:481−4.
153. Milner, J., E. A. Medcalf, and A. C. Cook. 1991. Tumor suppressor p53: analysis of wildtype and mutant p53 complexes. Mol Cell Biol 11:12−9.
154. Minna, J. D., J. Schutte, J. Viallet, F. Thomas, F. J. Kaye, T. Takahashi, M. Nau, J. Whang-Peng, M. Birrer, and A. F. Gazdar. 1989. Transcription factors and recessive oncogenes in the pathogenesis of human lung cancer. Int J Cancer Suppl 4:32−4.
155. Miyashita, T., S. Krajewski, M. Krajewska, H. G. Wang, H. K. Lin, D. A. Liebermann, B. Hoffman, and J. C. Reed. 1994. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9:1799−805.
156. Miyashita, T., and J. C. Reed. 1995. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293−9.
157. Muller, B. F., D. Paulsen, and W. Deppert. 1996. Specific binding of MAR/SAR DNAelements by mutant p53. Oncogene 12:1941−52.
158. Nacht, M., A. Strasser, Y. R. Chan, A. W. Harris, M. Schlissel, R. T. Bronson, and T. Jacks. 1996. Mutations in the p53 and SCID genes cooperate in tumorigenesis. Genes Dev 10:2055−66.
159. Nelson, W. G., and M. B. Kastan. 1994. DNA strand breaks: the DNA template alterations that trigger p53- dependent DNA damage response pathways. Mol Cell Biol 14:181 523.
160. Nguyen, K. T., B. Liu, K. Ueda, M. M. Gottesman, I. Pastan, and K. V. Chin. 1994 Transactivation of the human multidrug resistance (MDR1) gene promoter by p53 mutants. Oncol Res 6:71−7.
161. Niewolik, D., В. Vojtesek, and J. Kovarik. 1995. p53 derived from human tumour cell lines and containing distinct point mutations can be activated to bind its consensus target sequence. Oncogene 10:881−90.
162. Nigro, J. M., S. J. Baker, A. C. Preisinger, J. M. Jessup, R. Hostetter, K. Cleary, S. H. Bigner, N. Davidson, S. Baylin, P. Devilee, and et al. 1989. Mutations in the p53 gene occur in diverse human tumour types. Nature 342:705−8.
163. Oliner, J. D. 1993. Discerning the function of p53 by examining its molecular interactions. Bioessays 15:703−7.
164. Osifchin, N. E., D. Jiang, N. Ohtani-Fujita, T. Fujita, M. Carroza, S. J. Kim, T. Sakai, and P. D. Robbins. 1994. Identification of a p53 binding site in the human retinoblastoma susceptibility gene promoter. J Biol Chem 269:6383−9.
165. Осовская, В. С., Б. П. Копнин, Н. Т. Райхлин, Е. Смирнова, В. С. Прасолов, П. М. Чумаков. 1995. Влияние на различные линии клеток кДНК р53, экспрессируемой под контролем экзогенного гомологичного промотора. Молекулярная биология 29:61−70.
166. Ouchi, Т., А. N. Monteiro, A. August, S. A. Aaronson, and Н. Hanafusa. 1998 BRCA1 regulates p53-dependent gene expression. Proc Natl Acad Sci U S A 95:2302−6.
167. Parada, L. F., H. Land, R A. Weinberg, D. Wolf, and V. Rotter. 1984. Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature 312:649−51.
168. Pear, W. S., G. P. Nolan, M. L. Scott, and D. Baltimore. 1993. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci U S A 90:8392−6.
169. Picksley, S. M., B. Vojtesek, A. Sparks, and D. P. Lane. 1994. Immunochemical analysis of the interaction of p53 with MDM2-~fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene 9:2523−9.
170. Pietenpol, J. A., T. Tokino, S. Thiagalingam, W. S. el-Deiry, K. W. Kinzler, and B. Vogelstein. 1994. Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc Natl Acad Sci U S A 91:1998−2002.
171. Polyak, K., Y. Xia, J. L. Zweier, K. W. Kinzler, and B. Vogelstein. 1997 A model for p53-induced apoptosis see comments. Nature 389:300−5.
172. Prasolov, V. S., and P. M. Chumakov. 1988. Antisense RNA p53 inhibits proliferation of normal and transformed cells., Mol Biol (Mosk) 22:1371−80.
173. Prives, C., and J. J. Manfredi. 1993. The p53 tumor suppressor protein: meeting review. Genes Dev 7:529−34.
174. Quelle, F. W., J. Wang, J. Feng, D. Wang, J. L. Cleveland, J. N. Ihle, and G. P. Zambetti. 1998. Cytokine rescue of p53-dependent apoptosis and cell cycle arrest is mediated by distinct Jak kinase signaling pathways. Genes Dev 12:1099−107.
175. Querido, E., J. G. Teodoro, and P. E. Branton. 1997. Accumulation of p53 induced by the adenovirus El A protein requires regions involved in the stimulation of DNA synthesis. J Virol 71:3526−33.
176. Radfar, A., I. Unnikrishnan, H. W. Lee, R. A. DePinho, and N. Rosenberg. 1998 pl9(Arf) induces p53-dependent apoptosis during abelson virus-mediated pre-B cell transformation. ProcNatl Acad Sci U S A 95:13 194−9.
177. Raycroft, L., J. R Schmidt, K, Yoas, M. M. Hao, and G. Lozano. 1991. Analysis of p53 mutants for transcriptional activity. Mol Cell Biol 11:6067−74.
178. Reinke, V., and G. Lozano. 1997. The p53 targets mdm2 and Fas are not required as mediators of apoptosis in vivo. Oncogene 15:1527−34.
179. Reisman, D., N. B. Elkind, B. Roy, J. Beamon, and V. Rotter. 1993 c-Myc trans-activates the p53 promoter through a required downstream CACGTG motif. Cell Growth Differ 4:57−65.
180. Rotter, V., R. Aloni-Grinstein, D. Schwartz, N. B. Elkind, A. Simons, R. Wolkowicz, M. Lavigne, P. Beserman, A. Kapon, and N. Goldfinger. 1994. Does wild-type p53 play a role in normal cell differentiation? Semin Cancer Biol 5:229−36.
181. Roy, B., J. Beamon, E. Balint, and D. Reisman. 1994. Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors. Mol Cell Biol 14:7805−15.
182. Ruaro, E. M., L. Collavin, G. Del Sal, R. Haffner, M. Oren, A. J. Levine, and C. Schneider. 1997. A proline-rich motif in p53 is required for transactivation-independent growth arrest as induced by Gasl. Proc Natl Acad Sci U S A 94:4675−80.
183. Ryan, J. J., and M. F. Clarke. 1994. Alteration of p53 conformation and induction of apoptosis in a murine erythroleukemia cell line by dimethylsulfoxide. Leuk Res 18:617−21.
184. Ryan, J. J., E. Prochownik, C. A. Gottlieb, I. J. Apel, R. Merino, G. Nunez, and M. F. Clarke. 1994. c-myc and bcl-2 modulate p53 function by altering p53 subcellular trafficking during the cell cycle. Proc Natl Acad Sci U S A 91:5878−82.
185. Ryan, K. M., and K. H. Vousden. 1998. Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest. Mol Cell Biol 18:3692−8.
186. Sabbatini, P., S. K. Chiou, L. Rao, and E. White. 1995. Modulation of p53-mediated transcriptional repression and apoptosis by the adenovirus E1B 19K protein. Mol Cell Biol 15:1060−70.
187. Sakaguchi, K., J. E. Herrera, S. Saito, T. Miki, M. Bustin, A. Vassilev, C. W. Anderson, and E. Appella. 1998. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev 12:2831−41.
188. Sakamuro, D., P. Sabbatini, E. White, and G. C. Prendergast. 1997 The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene 15:887−98.
189. Sambrook, J., E. Fritsch, and T. Maniatis. 1989. Molecular Cloning. Cold Spring Harbor Laboratory Press, New York.
190. Samuelson, A. V., and S. W. Lowe. 1997. Selective induction of p53 and chemosensitivity in RB-deficient cells by El A mutants unable to bind the RB-related proteins. Proc Natl Acad Sci U S A 94:12 094−9.
191. Scheffner, M., J. M. Huibregtse, R. D. Vierstra, and P. M. Howley. 1993 The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75:495−505.
192. Scheffner, M., U. Nuber, and J. M. Huibregtse. 1995. Protein ubiquitination involving an E1-E2-E3 enzyme ubiquitin thioester cascade. Nature 373:81−3.
193. Scheffner, M., B. A. Werness, J. M. Huibregtse, A. J. Levine, and P. M. Howley. 1990 The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129−36.
194. Schneider, E., M. Montenarh, and P. Wagner. 1998. Regulation of CAK kinase activity by p53 In Process Citation., Oncogene 17:2733−41.
195. Selivanova, G., V. Iotsova, I. Okan, M. Fritsche, M. Strom, B. Groner, R. C. Grafstrom, and K. G. Wiman. 1997. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat Med 3:632−8.
196. Serrano, M., A. W. Lin, M. E. McCurrach, D. Beach, and S. W. Lowe. 1997 Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and pl6INK4a. Cell 88:593−602.
197. Seto, E., A. Usheva, G. P. Zambetti, J. Momand, N. Horikoshi, R. Weinmann, A. J. Levine, and T. Shenk. 1992. Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc Natl Acad Sci U S A 89:12 028−32.
198. Shaulian, E., I. Haviv, Y. Shaul, and M. Oren. 1995. Transcriptional repression by the C-terminal domain of p53. Oncogene 10:671−80.
199. Shaulian, E., A. Zauberman, D. Ginsberg, and M. Oren. 1992. Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding. Mol Cell Biol 12:5581−92.
200. Shaulsky, G., A. Ben-Ze'ev, and V. Rotter. 1990. Subcellular distribution of the p53 protein during the cell cycle ofBalb/c 3T3 cells. Oncogene 5:1707−11.
201. Shieh, S. Y., M. Ikeda, Y. Taya, and C. Prives. 1997. DNA damage-induced phosphorylation ofp53 alleviates inhibition by MDM2. Cell 91:325−34.
202. Soussi, T., C. Caron de Fromentel, and P. May. 1990. Structural aspects of the p53 protein in relation to gene evolution. Oncogene 5:945−52.
203. Srivastava, S., Z. Q. Zou, K. Pirollo, W. Blattner, and E. H. Chang. 1990 Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome see comments. Nature 348:747−9.
204. Stewart, N., G. G. Hicks, F. Paraskevas, and M. Mowat. 1995. Evidence for a second cell cycle block at G2/M by p53. Oncogene 10:109−15.
205. Sturzbecher, H. W., C. Addison, and J. R. Jenkins. 1988. Characterization of mutant p53-hsp72/73 protein-protein complexes by transient expression in monkey COS cells. Mol Cell Biol 8:3740−7.
206. Sturzbecher, H. W., R. Brain, C. Addison, K. Rudge, M. Remm, M. Grimaldi, E. Keenan, and J. R. Jenkins. 1992. A C-terminal alpha-helix plus basic region motif is the major structural determinant of p53 tetramerization. Oncogene 7:1513−23.
207. Sturzbecher, H. W., P. Chumakov, W. J. Welch, and J. R. Jenkins. 1987 Mutant p53 proteins bind hsp 72/73 cellular heat shock-related proteins in SV40-transformed monkey cells. Oncogene 1:201−11.
208. Subler, M. A., D. W. Martin, and S. Deb. 1994. Activation of the human immunodeficiency virus type 1 long terminal repeat by transforming mutants of human p53. J Virol 68:103−10.
209. Subler, M. A., D. W. Martin, and S. Deb. 1994. Overlapping domains on the p53 protein regulate its transcriptional activation and repression functions. Oncogene 9:1351−9.
210. Sullivan, G. F., P. S. Amenta, J. D. Villanueva, C. J. Alvarez, J. M. Yang, and W. N. Hait. 1998. The expression of drug resistance gene products during the progression of human prostate cancer. Clin Cancer Res 4:1393−403.
211. Tahara, H., E. Sato, A. Noda, and T. Ide. 1995. Increase in expression level of p21sdil/cipl/wafl with increasing division age in both normal and SV40-transformed human fibroblasts. Oncogene 10:835−40.
212. Takahashi, T., H. Suzuki, T. Hida, Y. Sekido, Y. Ariyoshi, and R. Ueda. 1991 The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. Oncogene 6:1775−8.
213. Thut, C. J., J. L. Chen, R. Klemm, and R. Tjian. 1995. p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. Science 267:100−4.
214. Ullrich, S. J., W. E. Mercer, and E. Appella. 1992. Human wild-type p53 adopts a unique conformational and phosphorylation state in vivo during growth arrest of glioblastoma cells. Oncogene 7:1635−43.
215. Unger, T., J. A. Mietz, M. Scheffner, C. L. Yee, and P. M. Howley. 1993 Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression. Mol Cell Biol 13:5186−94.
216. Vojtesek, B., and D. P. Lane. 1993. Regulation of p53 protein expression in human breast cancer cell lines. J Cell Sci 105:607−12.
217. Vousden, K. H., B. Vojtesek, C. Fisher, and D. Lane. 1993. HPV-16 E7 or adenovirus El A can overcome the growth arrest of cells immortalized with a temperature-sensitive p53. Oncogene 8:1697−702.
218. Waga, S., G. J. Hannon, D. Beach, and B. Stillman. 1994. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA see comments. Nature 369:574−8.
219. Wagner, A. J., J. M. Kokontis, and N. Hay. 1994. Myc-mediated apoptosis requires wildtype p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21wafl/cipl. Genes Dev 8:2817−30.
220. Walker, K. K., and A. J. Levine. 1996. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci U S A 93:15 335−40.
221. Wang, Q., G. P. Zambetti, and D. P. Suttle. 1997. Inhibition of DNA topoisomerase II alpha gene expression by the p53 tumor suppressor. Mol Cell Biol 17:389−97.
222. Wang, X. W., H. Yeh, L. Schaeffer, R. Roy, V. Moncollin, J. M. Egly, Z. Wang, E. C. Freidberg, M. K. Evans, B. G. Taffe, and et al. 1995. p53 modulation of TFIM-associated nucleotide excision repair activity. Nat Genet 10:188−95.
223. Werness, B. A., A. J. Levine, and P. M. Howley. 1990. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248:76−9.
224. White, E. 1994. Tumour biology. p53, guardian of Rb news- comment. Nature 371:21−2.
225. Wieczorek, A. M., J. L. Waterman, M. J. Waterman, and T. D. Halazonetis. 1996. Structure-based rescue of common tumor-derived p53 mutants. Nat Med 2:1143−6.
226. Wu, G. S., P. Saftig, C. Peters, and W. S. El-Deiry. 1998. Potential role for cathepsin D in p53-dependent tumor suppression and chemosensitivity. Oncogene 16:2177−83.
227. Wu, H., and G. Lozano. 1994. NF-kappa B activation of p53. A potential mechanism for suppressing cell growth in response to stress. J Biol Chem 269:20 067−74.
228. Xiao, Z. X., J. Chen, A. J. Levine, N. Modjtahedi, J. Xing, W. R. Sellers, and D. M. Livingston. 1995. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375:694−8.
229. Xu, Y., and D. Baltimore. 1996. Dual roles of ATM in the cellular response to radiation and in cell growth control see comments. Genes Dev 10:2401−10.
230. Yeung, M. C., and A. S. Lau. 1998. Tumor suppressor p53 as a component of the tumor necrosis factor- induced, protein kinase PKR-mediated apoptotic pathway in human promonocyte U937 cells. J Biol Chem 273:25 198−202.
231. Yew, P. R., and A. J. Berk. 1992. Inhibition of p53 transactivation required for transformation by adenovirus early IB protein. Nature 357:82−5.
232. Yewdell, J. W., J. V. Gannon, and D. P. Lane. 1986. Monoclonal antibody analysis of p53 expression in normal and transformed cells. J Virol 59:444−52.
233. Yin, Y., M. A. Tainsky, F. Z. Bischoff, L. C. Strong, and G. M. Wahl. 1992 Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70:937−48.
234. Yin, Y., Y. Terauchi, G. G. Solomon, S. Aizawa, P. N. Rangarajan, Y. Yazaki, T. Kadowaki, and J. C. Barrett. 1998. Involvement of p85 in p53-dependent apoptotic response to oxidative stress. Nature 391:707−10.
235. Yonish-Rouach, E., D. Resnitzky, J. Lotem, L. Sachs, A. Kimchi, and M. Oren. 1991. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352:345−7.
236. Zerrahn, J., W. Deppert, D. Weidemann, T. Patschinsky, F. Richards, and J. Milner.1992. Correlation between the conformational phenotype of p53 and its subcellular location. Oncogene 7:1371−81.
237. Zhan, Q., U. Kontny, M. Iglesias, I. Alamo, Jr., K. Yu, M. C. Hollander, C. D. Woodworth, and A. J. Fornace, Jr. 1999. Inhibitory effect of Bcl-2 on p53-mediated transactivation following genotoxic stress. Oncogene 18:297−304.
238. Zhang, S. Y., B. Ruggeri, P. Agarwal, A. F. Sorling, T. Obara, H. Ura, M. Namiki, and A. J. Klein-Szanto. 1994. Immunohistochemical analysis of p53 expression in human pancreatic carcinomas. Arch Pathol Lab Med 118:150−4.
239. Zhang, W., X. Y. Guo, and A. B. Deisseroth. 1994. The requirement of the carboxyl terminus of p53 for DNA binding and transcriptional activation depends on the specific p53 binding DNA element. Oncogene 9:2513−21.
240. Zhang, W., G. Hu, E. Estey, J. Hester, and A. Deisseroth. 1992. Altered conformation of the p53 protein in myeloid leukemia cells and mitogen-stimulated normal blood cells. Oncogene 7:1645−7.
241. Zhang, Y., Y. Xiong, and W. G. Yarbrough. 1998. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92:725−34.
242. Zhu, J., W. Zhou, J. Jiang, and X. Chen. 1998. Identification of a novel p53 functional domain that is necessary for mediating apoptosis. J Biol Chem 273:13 030−6.
243. Zindy, F., C. M. Eischen, D. H. Randle, T. Kamijo, J. L. Cleveland, C. J. Sherr, and M. F. Roussel. 1998. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 12:2424−33.